Status:
COMPLETED
Systematic Review and Meta-Analysis of Multaq® for Safety in Atrial Fibrillation
Lead Sponsor:
Sanofi
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
A systematic literature review (SLR) will be conducted to understand the landscape of evidence on the relative safety and effectiveness/efficacy of dronedarone compared to sotalol in patients with AFi...
Eligibility Criteria
Inclusion
- Following eligibility criteria are defined to select relevant studies from the literature
- Adults with Atrial Fibrillation(AFib) (non-permanent, including paroxysmal or persistent, long-standing persistent AFib \[over 12 months\]))
- Participants have received either Dronedarone or Sotalol
- controlled clinical trials or comparative observational studies( prospective/retrospective cohort, case-control studies, population-based studies or registry based studies
Exclusion
- Exclusion criteria for potential participants are:
- Children/adolescents
- Permanent atrial fibrillation (AFib)
Key Trial Info
Start Date :
September 24 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2022
Estimated Enrollment :
87810 Patients enrolled
Trial Details
Trial ID
NCT05279833
Start Date
September 24 2021
End Date
March 31 2022
Last Update
January 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis, France
Chilly-Mazarin, France, 91380